Background: Against the background of limited resources, the rise in the cost of therapy as well as in the number of cancer patients fuels the discussion about the necessity to ration, i.e., setting limits to beneficial treatment for cost reasons. Recently, we presented the self-reported prevalence of bedside rationing among German oncologists. Here, we describe oncologists' views on cost containment strategies and their role therein. Methods: We performed an online survey including structured questions and free field sections with the members of the German Society of Hematology and Oncology. Results: In the perception of oncologists, cost considerations and negotiations are gaining in importance and consume considerable working time. This negatively affects job satisfaction in 72% of the 345 respondents. Oncologists are concerned that the quality of care will suffer from rationalization and implicit rationing. They are ambivalent as to who is best suited to decide about resource rationing: 66% support the view that limits for costly procedures should be set by a form of commission; nevertheless, 48% consider physicians as the best decision makers in these situations. Conclusion: We suggest a broad public discussion and an interdisciplinary debate among the oncology community to define and legitimize decisions on rationing by setting explicit criteria.

Journal Section:
Original Article
Keywords:
Rationing cancer care, Cost-effectiveness, Withholding beneficial treatment, Role of oncologists, Quantitative and qualitative data
1.
Smith TJ, Hillner BE: Bending the cost curve in cancer care. N Engl J Med 2011;364:2060-2065.
2.
Elkin EB, Bach PB: Cancer's next frontier: addressing high and increasing costs. Jama 2010;303:1086-1087.
3.
Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ: When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010;102:82-88.
4.
Oduncu FS: Priority-setting, rationing and cost-effectiveness in the German health care system. Med Health Care Philos 2013;16:327-339.
5.
Winkler E: Rationalisierung, Rationierung, Priorisierung: Terminologie und ethische Begründungsansätze zur Allokation bei begrenzten Ressourcen in der Hämatologie/Onkologie. Oncol Res Treat 2011;34(suppl 1):2-5.
6.
Hurst SA, Slowther AM, Forde R, Pegoraro R, Reiter-Theil S, Perrier A, Garrett-Mayer E, Danis M: Prevalence and determinants of physician bedside rationing: data from Europe. J Gen Intern Med 2006;21:1138-1143.
7.
Strech D, Synofzik M, Marckmann G: How physicians allocate scarce resources at the bedside: a systematic review of qualitative studies. J Med Philos 2008;33:80-99.
8.
Levinsky NG: The doctor's master. N Engl J Med 1984;311:1573-1575.
9.
Pearson SD: Caring and cost: the challenge for physician advocacy. Ann Intern Med 2000;133:148-153.
10.
Cohen AB: The debate over health care rationing: déjà vu all over again? Inquiry 2012;49:90-100.
11.
Weinstein MC: Should physicians be gatekeepers of medical resources? J Med Ethics 2001;27:268-274.
12.
Scheunemann LP, White DB: The physician as rationer: uncertainty about the physician's role obligations. Semin Respir Crit Care Med 2012;33:421-426.
13.
Sulmasy DP: Cancer care, money, and the value of life: whose justice? Which rationality? J Clin Oncol 2007;25:217-222.
14.
Kumar P, Moy B: The cost of cancer care - balancing our duties to patients versus society: are they mutually exclusive? Oncologist 2013;18:347-349.
15.
Sulmasy D, Moy B: Debating the oncologist's role in defining the value of cancer care: our duty is to our patients. J Clin Oncol 2014;32:4039-4041.
16.
The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract 2014;10:119-142.
17.
Schildmann J, Tan J, Vollmann J: (Economical aspects in clinical practice: results from an explorative interview study on the perspectives of oncologists in Germany and England). Onkologie 2011;34(suppl 1):20-24.
18.
Strech D, Danis M, Lob M, Marckmann G: (Extent and impact of bedside rationing in German hospitals: results of a representative survey among physicians). Dtsch Med Wochenschr 2009;134:1261-1266.
19.
Lange J, Gonner C, Vollmann J, Rauprich O: (Rationing in German health care with particular consideration of oncology: view points of German stakeholders - a qualitative interview study). Gesundheitswesen 2015;77:8-15.
20.
Krause SW, Schildmann J, Lotze C, Winkler EC: Rationing cancer care: a survey among the members of the German Society of Hematology and Oncology. J Natl Compr Canc Netw 2013;11:658-665.
21.
O'Cathain A, Thomas KJ: ‘Any other comments?' Open questions on questionnaires - a bane or a bonus to research? BMC Med Res Methodol 2004;4:1-7.
22.
Bankauskaite V, Saarelma O: Why are people dissatisfied with medical care services in Lithuania? A qualitative study using responses to open-ended questions. Int J Qual Health Care 2003;15:23-29.
23.
Steckler A, McLeroy KR, Goodman RM, Bird ST, McCormick L: Toward integrating qualitative and quantitative methods: an introduction. Health Educ Q 1992;19:1-8.
24.
Mayring P: Qualitative content analysis. FQS 2000;1:art 20.
25.
Mayring P: Qualitative Content Analysis: Theoretical Foundation, Basic Procedures and Software Solution. Klagenfurt, 2014.
26.
Mayring P: Qualitative Inhaltsanalyse: Grundlagen und Techniken. Weinheim, Beltz, 2010.
27.
Ubel PA, Arnold RM: The unbearable rightness of bedside rationing. Physician duties in a climate of cost containment. Arch Intern Med 1995;155:1837-1842.
28.
Fojo T, Grady C: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-1048.
29.
Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL; American Society of Clinical Oncology: American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015;33:2563-2577.
30.
Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-1573.
31.
Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wentz R, Kwan I: Increasing response rates to postal questionnaires: systematic review. BMJ 2002;324:1183.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.